HK1215670A1 - 抗體 - Google Patents
抗體Info
- Publication number
- HK1215670A1 HK1215670A1 HK16103611.5A HK16103611A HK1215670A1 HK 1215670 A1 HK1215670 A1 HK 1215670A1 HK 16103611 A HK16103611 A HK 16103611A HK 1215670 A1 HK1215670 A1 HK 1215670A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gdf15
- antibodies
- gdf15 antibodies
- antibodies gdf15
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745508P | 2012-12-21 | 2012-12-21 | |
| US201361827325P | 2013-05-24 | 2013-05-24 | |
| PCT/US2013/077139 WO2014100689A1 (en) | 2012-12-21 | 2013-12-20 | Anti-gdf15 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1215670A1 true HK1215670A1 (zh) | 2016-09-09 |
Family
ID=50069279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16103611.5A HK1215670A1 (zh) | 2012-12-21 | 2016-03-30 | 抗體 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9175076B2 (zh) |
| EP (2) | EP2934584B1 (zh) |
| JP (3) | JP6758832B2 (zh) |
| KR (1) | KR102208861B1 (zh) |
| CN (1) | CN105073133B (zh) |
| AR (1) | AR094271A1 (zh) |
| AU (1) | AU2013364133B2 (zh) |
| CA (1) | CA2896076C (zh) |
| DK (1) | DK2934584T3 (zh) |
| EA (1) | EA038645B1 (zh) |
| ES (1) | ES2791183T3 (zh) |
| HK (1) | HK1215670A1 (zh) |
| MX (1) | MX370720B (zh) |
| WO (1) | WO2014100689A1 (zh) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102469853B1 (ko) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| CN103533951B (zh) | 2011-04-08 | 2017-04-19 | 安姆根有限公司 | 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法 |
| US9714276B2 (en) | 2012-01-26 | 2017-07-25 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) polypeptides |
| WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| WO2014049087A1 (en) | 2012-09-26 | 2014-04-03 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
| DK2934584T3 (da) * | 2012-12-21 | 2020-05-18 | Aveo Pharmaceuticals Inc | Anti-gdf15-antistoffer |
| EP2950807B1 (en) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| EA202092386A1 (ru) | 2013-07-31 | 2021-04-30 | Эмджен Инк. | Конструкции на основе фактора дифференцировки и роста 15 (gdf15) |
| AU2014342316B2 (en) * | 2013-10-31 | 2019-07-25 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| JP6640083B2 (ja) | 2013-11-21 | 2020-02-05 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 肺高血圧症を治療するための組成物および方法 |
| EP3119424A4 (en) | 2014-03-19 | 2017-09-13 | MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
| FI3653644T3 (fi) * | 2014-03-26 | 2023-12-12 | Univ Wuerzburg J Maximilians | Monoklonaalisia vasta-aineita kasvu- ja erilaistumistekijä 15:tä (gdf-15) vastaan sekä niiden käyttöjä syöpään liittyvän kakeksian ja syövän hoitoon |
| GB2524552B (en) * | 2014-03-26 | 2017-07-12 | Julius-Maximilians-Universitãt Wurzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer |
| GB2524553C (en) * | 2014-03-26 | 2017-07-19 | Julius-Maximilians-Universitãt Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia |
| EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| US20170137505A1 (en) * | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| KR20170065026A (ko) | 2014-07-30 | 2017-06-12 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애 치료용으로 이용되는 조성물 및 방법 |
| CN106794233B (zh) * | 2014-08-01 | 2021-11-12 | 布里格姆及妇女医院股份有限公司 | 与肺动脉高压的治疗有关的组合物和方法 |
| HUE054670T2 (hu) | 2014-09-25 | 2021-09-28 | Aveo Pharmaceuticals Inc | Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával |
| WO2016050796A1 (en) * | 2014-09-30 | 2016-04-07 | Universiteit Gent | A method of treating joint disease |
| WO2016069925A1 (en) | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
| CA2961587A1 (en) | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| PE20221834A1 (es) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina |
| KR20170110129A (ko) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| AU2016253126B2 (en) * | 2015-04-23 | 2020-01-30 | Haemalogix Pty. Ltd. | Kappa myeloma antigen chimeric antigen receptors and uses thereof |
| CN106349388B (zh) * | 2015-07-17 | 2021-04-02 | 上海佳文英莉生物技术有限公司 | 一种促细胞程序性坏死抗体及其应用 |
| GB201512733D0 (en) * | 2015-07-20 | 2015-08-26 | Genagon Therapeutics Ab | Therapeutic agents for treating conditions associated with elevated GDF15 |
| CA3000290C (en) | 2015-10-02 | 2023-02-21 | Julius-Maximilians-Universitat Wurzburg | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| IL299478A (en) | 2015-10-02 | 2023-02-01 | Univ Wuerzburg J Maximilians | Combined treatment using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint inhibitors |
| US11267875B2 (en) | 2015-10-28 | 2022-03-08 | Yale University | Humanized anti-DKK2 antibody and uses thereof |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| AU2017214277B2 (en) * | 2016-02-01 | 2020-02-27 | Eli Lilly And Company | Parathyroid hormone – anti-RANKL antibody fusion compounds |
| CN108697795A (zh) * | 2016-02-29 | 2018-10-23 | 伊莱利利公司 | Gfral受体疗法 |
| EP3423097A4 (en) * | 2016-03-04 | 2019-08-21 | NGM Biopharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR MODULATING BODY WEIGHT |
| TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
| US11312766B2 (en) * | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| CN109790223A (zh) * | 2016-08-05 | 2019-05-21 | 阿拉科斯有限责任公司 | 用于治疗癌症的抗siglec-7抗体 |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| JP7134960B2 (ja) * | 2016-12-06 | 2022-09-12 | セントビンセンツ ホスピタル シドニー リミテッド | 肥満及び摂食障害の治療 |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| AU2018304173A1 (en) | 2017-07-17 | 2020-01-30 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type III domains and methods of using the same |
| CA3087968A1 (en) | 2018-01-11 | 2019-07-18 | Allakos, Inc. | Anti-siglec-7 antibodies having reduced effector function |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CR20200510A (es) | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
| US20210340263A1 (en) * | 2018-08-09 | 2021-11-04 | The Wistar Institute | Anti-Follicule Stimulating Hormone Receptor Antibodies |
| AU2019323790A1 (en) * | 2018-08-20 | 2021-03-11 | Pfizer Inc. | Anti-GDF15 antibodies, compositions and methods of use |
| KR102238927B1 (ko) * | 2018-08-30 | 2021-04-12 | 서울대학교산학협력단 | 세포 내에서 nag-1 단백질의 이동을 조절하는 펩티드 및 이의 용도 |
| US20220048995A1 (en) * | 2018-09-10 | 2022-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an inhibitor of ntsr1 activation or expression for preventing weight loss, muscle loss, and protein blood level decrease in subjects in need thereof |
| WO2021111636A1 (ja) * | 2019-12-06 | 2021-06-10 | 大塚製薬株式会社 | 抗ｇｄｆ１５抗体 |
| CN114560938B (zh) * | 2020-03-30 | 2023-05-23 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
| CN115698073A (zh) * | 2020-06-04 | 2023-02-03 | 大邱庆北科学技术院 | Gfral拮抗抗体及其用途 |
| AR125037A1 (es) * | 2021-03-08 | 2023-05-31 | Medimmune Llc | Anticuerpos dirigidos contra gdf-15 |
| CA3215737A1 (en) | 2021-03-31 | 2022-10-06 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
| CA3228576A1 (en) | 2021-08-10 | 2023-02-16 | Byomass Inc. | Anti-gdf15 antibodies, compositions and uses thereof |
| WO2023079430A1 (en) | 2021-11-02 | 2023-05-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
| WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
| WO2023141815A1 (zh) * | 2022-01-26 | 2023-08-03 | 康源博创生物科技(北京)有限公司 | 抗生长分化因子15的抗体分子及其应用 |
| WO2023217068A1 (zh) * | 2022-05-09 | 2023-11-16 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别gdf15的抗体及其应用 |
| CN116444667B (zh) * | 2023-06-13 | 2023-09-01 | 上海驯鹿生物技术有限公司 | 一种靶向gdf15的全人源抗体及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1994003599A1 (en) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
| US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| WO1996018730A1 (en) | 1994-12-15 | 1996-06-20 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| DE69637844D1 (de) | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | Neues tgf-beta-ahnliches cytokin |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| EP1117805A2 (en) | 1998-10-07 | 2001-07-25 | STRYKER CORPORATION (a Michigan corporation) | Modified tgf-beta superfamily proteins |
| US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
| CA2372119A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh | Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily |
| ES2300325T3 (es) | 2000-04-20 | 2008-06-16 | St Vincent's Hospital Sydney Limited | Ensayo diagnostico que implica la citoquina 1 inhibitoria de macrofagos (mc1). |
| WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| WO2004041170A2 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004043385A2 (en) | 2002-11-08 | 2004-05-27 | Barnes-Jewish Hospital | Methods and compositions for prostate epithelial cell differentiation |
| US20060188889A1 (en) | 2003-11-04 | 2006-08-24 | Christopher Burgess | Use of differentially expressed nucleic acid sequences as biomarkers for cancer |
| WO2005036608A2 (en) | 2003-10-10 | 2005-04-21 | That Corporation | Low-power integrated-circuit signal processor with wide dynamic range |
| JP4829780B2 (ja) | 2004-03-26 | 2011-12-07 | 武田薬品工業株式会社 | 呼吸器疾患の予防・治療剤 |
| EP2774620A1 (en) * | 2004-04-13 | 2014-09-10 | St Vincent's Hospital Sydney Limited | Method for modulating weight loss |
| CA2534871C (en) | 2006-02-15 | 2015-08-04 | The Ohio State University Research Foundation | Three-gene test to differentiate malignant from benign thyroid nodules |
| US20070237713A1 (en) | 2006-04-04 | 2007-10-11 | Fan Rong A | PCan065 Antibody Compositions and Methods of Use |
| BRPI0715126B8 (pt) | 2006-08-04 | 2021-07-27 | Medizinische Hochschule Hannover | métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15 |
| EP1884777A1 (en) | 2006-08-04 | 2008-02-06 | Medizinische Hochschule Hannover | Means and methods for assessing the risk of cardiac interventions based on GDF-15 |
| CN101854947A (zh) * | 2007-08-16 | 2010-10-06 | 圣文森特医院悉尼有限公司 | 用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法 |
| EP2209486A1 (en) | 2007-10-09 | 2010-07-28 | St Vincent's Hospital Sydney Limited | A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| EP2103943A1 (en) | 2008-03-20 | 2009-09-23 | F. Hoffman-la Roche AG | GDF-15 for assessing a cardiovascular risk with respect to the administration of antiinflammatory drugs |
| EP2279419A1 (en) | 2008-05-20 | 2011-02-02 | Roche Diagnostics GmbH | Gdf-15 as biomarker in type 1 diabetes |
| GB0902793D0 (en) * | 2009-02-20 | 2009-04-08 | Univ Gent | GDF15 as molecular tool to monitor and enhance phenotypic stability of articular chondrocytes |
| US9212221B2 (en) * | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
| GB201004739D0 (en) | 2010-03-22 | 2010-05-05 | Prosidion Ltd | Receptor modulators |
| WO2012113103A1 (en) | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| DK2934584T3 (da) | 2012-12-21 | 2020-05-18 | Aveo Pharmaceuticals Inc | Anti-gdf15-antistoffer |
| EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| US20170137505A1 (en) | 2014-06-20 | 2017-05-18 | Aveo Pharmaceuticals, Inc. | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
-
2013
- 2013-12-20 DK DK13827058.2T patent/DK2934584T3/da active
- 2013-12-20 AR ARP130105017A patent/AR094271A1/es active IP Right Grant
- 2013-12-20 CA CA2896076A patent/CA2896076C/en active Active
- 2013-12-20 US US14/137,415 patent/US9175076B2/en active Active
- 2013-12-20 KR KR1020157019881A patent/KR102208861B1/ko active IP Right Grant
- 2013-12-20 JP JP2015549810A patent/JP6758832B2/ja active Active
- 2013-12-20 MX MX2015007751A patent/MX370720B/es active IP Right Grant
- 2013-12-20 AU AU2013364133A patent/AU2013364133B2/en active Active
- 2013-12-20 EA EA201591198A patent/EA038645B1/ru unknown
- 2013-12-20 EP EP13827058.2A patent/EP2934584B1/en active Active
- 2013-12-20 EP EP20156883.9A patent/EP3689370A1/en active Pending
- 2013-12-20 CN CN201380073317.1A patent/CN105073133B/zh active Active
- 2013-12-20 WO PCT/US2013/077139 patent/WO2014100689A1/en active Application Filing
- 2013-12-20 ES ES13827058T patent/ES2791183T3/es active Active
-
2015
- 2015-09-24 US US14/863,870 patent/US9725505B2/en active Active
-
2016
- 2016-03-30 HK HK16103611.5A patent/HK1215670A1/zh unknown
-
2017
- 2017-07-20 US US15/655,263 patent/US10597444B2/en active Active
-
2019
- 2019-01-21 JP JP2019007928A patent/JP2019056018A/ja not_active Withdrawn
-
2020
- 2020-03-19 US US16/824,034 patent/US11725047B2/en active Active
-
2021
- 2021-01-25 JP JP2021009528A patent/JP2021061864A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20140193427A1 (en) | 2014-07-10 |
| US10597444B2 (en) | 2020-03-24 |
| US20210101968A1 (en) | 2021-04-08 |
| EP2934584B1 (en) | 2020-02-19 |
| CN105073133A (zh) | 2015-11-18 |
| US11725047B2 (en) | 2023-08-15 |
| EA201591198A1 (ru) | 2015-11-30 |
| ES2791183T3 (es) | 2020-11-03 |
| KR20150100837A (ko) | 2015-09-02 |
| AU2013364133A1 (en) | 2015-07-16 |
| CN105073133B (zh) | 2021-04-20 |
| KR102208861B1 (ko) | 2021-01-27 |
| JP2016508984A (ja) | 2016-03-24 |
| US20160083465A1 (en) | 2016-03-24 |
| US9725505B2 (en) | 2017-08-08 |
| AR094271A1 (es) | 2015-07-22 |
| JP6758832B2 (ja) | 2020-09-30 |
| AU2013364133B2 (en) | 2018-10-11 |
| DK2934584T3 (da) | 2020-05-18 |
| JP2019056018A (ja) | 2019-04-11 |
| US9175076B2 (en) | 2015-11-03 |
| EA038645B1 (ru) | 2021-09-28 |
| JP2021061864A (ja) | 2021-04-22 |
| MX2015007751A (es) | 2015-11-30 |
| MX370720B (es) | 2019-12-20 |
| US20180142013A1 (en) | 2018-05-24 |
| CA2896076C (en) | 2022-12-06 |
| EP3689370A1 (en) | 2020-08-05 |
| BR112015014768A2 (pt) | 2017-10-10 |
| WO2014100689A1 (en) | 2014-06-26 |
| CA2896076A1 (en) | 2014-06-26 |
| EP2934584A1 (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1215670A1 (zh) | 抗體 | |
| IL264558A (en) | Anti–il–23p19 antibodies | |
| ZA201407509B (en) | Anti-fcrn antibodies | |
| HK1204571A1 (zh) | 蛋白酶調節的抗體 | |
| HK1210192A1 (zh) | 抗體 | |
| EP2930240A4 (en) | ANTI-FOLR1 ANTIBODY | |
| EP2844290A4 (en) | NOVEL ANTIBODIES | |
| ZA201407316B (en) | Anti-fgfr2 antibody | |
| EP2826790A4 (en) | GREMLIN-1 ANTIBODY | |
| ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
| HK1210186A1 (zh) | 抗體 | |
| IL235369B (en) | Anti-transglutaminase 2 antibodies | |
| PL2935330T3 (pl) | Przeciwciała przeciw notch3 | |
| EP2804876A4 (en) | NEW ANTIBODIES | |
| GB201220242D0 (en) | Antibody | |
| EP2848633A4 (en) | ANTI-CXADR ANTIBODY | |
| EP2811018A4 (en) | ANTI-BODY ANTI-sAPPß | |
| IL235188A0 (en) | Antibodies against c-pdgf | |
| GB201209584D0 (en) | Modified antibodies |